Abbott Laboratories (NYSE: ABT) and Dexcom (NASDAQ: DXCM) are two leading medical device companies that compete against one ...
Now that the Abbott Freestyle Libre has received FDA clearance, Abbott and Dexcom will be forced into tight competition in the US market. On Dexcom’s third quarter call, CEO Kevin Sayer spent some ...
Dexcom reported second-quarter results on Friday, July 26. Management lowered its forward revenue outlook because of unexpected challenges with its new glucose monitoring device. Dexcom's main ...
Two companies are making life a lot easier for people with diabetes. Abbott Laboratories (ABT 1.46%) and DexCom (DXCM 1.80%) market devices that allow for convenient monitoring of blood sugar levels ...
ORLANDO -- In a three-way head-to-head comparison of continuous glucose monitors (CGMs), all performed well in an outpatient setting in type 1 diabetes patients, researchers reported here. Comparing ...
DexCom has enormous runway for growth, not just in its home market - the U.S., but internationally as well. Manufacturing efficiencies could support their international ambitions while supporting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results